Trial Profile
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Everolimus; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 30 Sep 2020 Results (n=116) published in the Clinical Cancer Research
- 27 Apr 2020 Status changed from active, no longer recruiting to completed.
- 04 Oct 2019 Planned End Date changed from 16 Sep 2019 to 11 Sep 2020.